This page shows the latest Inovio news and features for those working in and with pharma, biotech and healthcare.
The US Food and Drug Administration (FDA) has placed a temporary hold on Inovio Pharmaceuticals’ mid-to-late stage coronavirus vaccine trial. ... Importantly, the clinical hold is not due to the occurrence of any adverse events related to the vaccine,
CEPI has already invested $4.4m in partnering agreements with Novavax and The University of Oxford to rapidly develop COVID-19 vaccine candidates, and it also announced initial funding to Inovio
Results at six months demonstrated 75% of patients were progression-free. A combination of three cancer immunotherapy drugs from Inovio and Sanofi/Regeneron has shown impressive results in glioblastoma multiforme (GBM), ... Newly-diagnosed GBM patients
Last year Inovio Pharma and GeneOne Life Sciences reported phase I data with their synthetic GLS-5700 DNA vaccine in the New England Journal of Medicine (NEJM), concluding that it was
AstraZeneca has signed a strategic-level licensing deal with Inovio for cancer vaccines that flesh out its cancer immunotherapy pipeline. ... The result is what Inovio claims is a 'best-in-class' T cell-stimulating therapy, generating fully functional
Among the small number of companies developing potential vaccines against MERS are Inovio Pharmaceuticals and partner company GeneOne Life Sciences, which recently announced plans to start a phase I trial of
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
Inovio Pharmaceuticals began testing its plasmid candidate in humans in April, putting it at the head of a pack of six groups that have DNA vaccines in development.
The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
Amendment to 2015 agreement. 80. Inovio Pharmaceuticals/ ApolloBio Corporation. VGX-3100, DNA immunotherapy to treat pre-cancers caused by human papillomavirus (phase II).
AstraZeneca deals. Subject. Headline $m. Inovio. Cancer vaccines. 727. Heptares. HTL 1071 and A2A receptor blocking compounds. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for cervical and head &neck cancer.
483. BioFire Diagnostics / BioMerieux. Acquisition. Invitro diagnostic company. 450. Inovio Pharma / Roche Holdings.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...